SCHEMBL23980841

SCHEMBL23980841

O=C(COc1c(Br)cccc1Br)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 2/20 0.50
HPGD P15428 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
GRM4 Q14833 2/20 0.49
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GSK3B P49841 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPK1 P28482 2/20 0.47
TRPA1 O75762 1/20 0.47
HIF1A Q16665 1/20 0.47
PTPN1 P18031 1/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 4/20 0.47
KDM4E B2RXH2 1/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
CES1 P23141 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378913 0.89 NPC1 (0.44) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL9787364 0.86 NPC1 (0.51) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL23980850 0.86 MAPT (0.52) NPC1RAB9AHPGDL3MBTL1GRM4
SCHEMBL18795961 0.86 NPC1 (0.47) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL11514166 0.82 KMT2A (0.68) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL7804236 0.82 GRM4 (0.64) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL28701599 0.82 L3MBTL1 (0.45) NPC1RAB9AHPGDTDP1L3MBTL1
SCHEMBL9646424 0.81 KMT2A (0.66) HPGDTDP1L3MBTL1SMN1; SMN2ALDH1A1
SCHEMBL27287038 0.80 MAPT (0.47) NPC1RAB9AHPGDL3MBTL1GRM4
SCHEMBL2393671 0.79 KMT2A (0.58) NPC1RAB9AHPGDTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552791-B2 Heterocyclic GLP-1 agonists GASHERBRUM BIO, INC. (US) 2026-02-17 US disclosed
EP-4143183-B1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC (US) 2025-10-22 EP disclosed
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2025-07-03 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS SHOUTI INC. 2023-09-21 US disclosed
EP-4143183-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-03-08 EP disclosed
CN-115667250-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-01-31 CN disclosed
WO-2021219019-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295154-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR NPC1 1207/4885RAB9A 788/4885HPGD 919/4885
US-12552791-B2 Heterocyclic GLP-1 agonists GLP1R, NPY1R, NPY2R NPC1 795/4885RAB9A 1582/4885HPGD 3363/4885
US-20250214999-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR NPC1 1207/4885RAB9A 788/4885HPGD 919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.